Funding for this research was provided by:
The Consortium for Eosinophilic Gastrointestinal Disease Researchers (U54 AI117804)
Office of Rare Diseases Research (U54 AI117804)
National Institute of Allergy and Infectious Diseases (U54 AI117804)
National Institute of Diabetes and Digestive and Kidney Diseases (U54 AI117804)
National Center for Advancing Translational Sciences (U54 AI117804)
Campaign Urging Research for Eosinophilic Disease (U54 AI117804)
American Partnership for Eosinophilic Disorders (U54 AI117804)
Campaign Urging Research for Eosinophilic Disease (U54 AI117804)
Eosinophilic Family Coalition (U54 AI117804)
Article History
First Online: 18 February 2018
Compliance with Ethical Standards
: Dr. Durrani reports funding from Sanofi/Regeneron.
: Dr. Mukkada reports funding from the NIH, PCORI, and Shire. He has done consulting work with hire.
: Dr. Guilbert reports personal fees from the American Board of Pediatrics; Pediatric Pulmonary Subboard, personal fees from Teva, personal fees from GSK, personal fees from Regeneron Pharmaceuticals, grants from NIH, other from UpToDate, personal fees from Merck, grants and personal fees from Sanofi/Regeneron, personal fees from Novartis/Regeneron, personal fees from Aviragen, and personal fees from GSK/Regneron, outside the submitted work.